American Heart Journal · 2016 · 103 citations · 20 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical PharmacologyInterventional CardiologyAnticoagulant TherapyAnticoagulation TherapyAntiplatelet TherapyAntithrombotic TherapyThrombosisThrombosis PreventionAntiplatelet DrugsCombination Antiplatelet TherapyLong-term AnticoagulationPerioperative Antiplatelet TherapyPeriprocedural Antithrombotic TherapyProphylactic AnticoagulationSystemic AnticoagulationTherapeutic Anticoagulation
BACKGROUND: Optimal antithrombotic treatment after transcatheter aortic valve replacement (TAVR) is unknown and determined empirically. The direct factor Xa inhibitor rivaroxaban may potentially reduce TAVR-related thrombotic complications and premature valve failure. DESIGN: GALILEO is an international, randomized, open-label, event-driven, phase III trial in more than 1,520 patients without an indication for oral anticoagulation who underwent a successful TAVR (ClinicalTrials.govNCT02556203). Patients are randomized (1:1 ratio), 1 to 7days after a successful TAVR, to either a rivaroxaban-based strategy or an antiplatelet-based strategy. In the experimental arm, subjects receive rivaroxaban (10mg once daily [OD]) plus acetylsalicylic acid (ASA, 75-100mg OD) for 90days followed by rivaroxaban alone. In the control arm, subjects receive clopidogrel (75mg OD) plus ASA (as above) for 90days followed by ASA alone. In case new-onset atrial fibrillation occurs after randomization, full oral anticoagulation will be implemented with maintenance of the original treatment assignment. The primary efficacy end point is the composite of all-cause death, stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep venous thrombosis, and systemic embolism. The primary safety end point is the composite of life-threatening, disabling, and major bleeding, according to the Valve Academic Research Consortium definitions. CONCLUSIONS: GALILEO will test the hypothesis that a rivaroxaban-based antithrombotic strategy reduces the risk of thromboembolic complications post-TAVR with an acceptable risk of bleeding compared with the currently recommended antiplatelet therapy-based strategy in subjects without need of chronic oral anticoagulation.
20
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine · 2011 · 9.4K citations · Full text
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
Craig R. Smith, Martin B. Leon, Michael J. Mack et al. · New England Journal of Medicine · 2011 · 6.3K citations · Full text
Medicine, Cardiology, Surgery +13
Burden of valvular heart diseases: a population-based study
Vuyisile T. Nkomo, Julius M. Gardin, Thomas N. Skelton et al. · The Lancet · 2006 · 4.8K citations
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
Roxana Mehran, Sunil V. Rao, Deepak L. Bhatt et al. · Circulation · 2011 · 4.4K citations
Medicine, Cardiology, Hematology +10